Spring Bank Pharmaceuticals, Inc. announced that Pamela Klein, M.D., has been elected as an independent member of its Board of Directors. Dr. Klein will also serve on the Science and Technology Committee of the Board of Directors. Dr. Klein is a principal and founder of PMK BioResearch, which offers strategic consulting in oncology drug development to corporate boards, management teams and the investment community. She previously served as Chief Medical Officer of Intellikine, which was acquired by Takeda Pharmaceuticals in 2011, and Vice President, Development, at Genentech. Dr. Klein also spent seven years at the National Cancer Institute as Research Director of the NCI-Navy Breast Care Center. Dr. Klein currently serves as a member of various scientific advisory boards as well as on the board of directors of argenx SE, a biotechnology company.